Radionuclide-based cancer imaging targeting the carcinoembryonic antigen

Biomarker Insights

Volumn 2008, Issue 3, 2008, Pages 435-451

  Hong, Hao ^a   Sun, Jiangtao ^a   Cai, Weibo ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Antibody; Antibody fragment; Carcinoembryonic antigen; Positron emission tomography (PET); Pretargeting; Single photon emission computed tomography (SPECT)

Indexed keywords

ARCITUMOMAB TC 99M; BROMINE 76; CARBON 11; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; COPPER 64; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; INDIUM 111; IODINE 123; IODINE 124; IODINE 125; IODINE 131; LABETUZUMAB; MACROGOL; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; RADIOISOTOPE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STREPTAVIDIN; TECHNETIUM 94M; TECHNETIUM 99M; TECHNETIUM DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBODY LABELING; ANTIGEN DETECTION; BREAST CANCER; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; GAMMA SCINTIGRAPHY; HUMAN; IMAGE QUALITY; IMMUNOHISTOCHEMISTRY; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; LIVER METASTASIS; LUNG CANCER; LUNG METASTASIS; LYMPH NODE METASTASIS; MOLECULAR IMAGING; NONHUMAN; PHOTON EMISSION TOMOGRAPHY; REVIEW; SCINTIMAMMOGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL IMAGING; THYROID CANCER;

EID: 54949106587     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/bmi.s1124     Document Type: Review

References (136)

1. Abdel-Nabi, H.H., Schwartz, A.N., Goldfogel, G. et al. 1988. Colorectal tumors: scintigraphy with In-111 anti-CEA monoclonal antibody and correlation with surgical, histopathologic and immunohistochemical findings. Radiology, 166:747-52.
2. Abdel-Nabi, H.H., Schwartz, A.N., Wechter, D.G. et al. 1991. Scintigraphic detection of gastric and pancreatic carcinomas with In-111 ZCE 025 monoclonal antibody. World J. Surg., 15:122-7.
3. Banerjee, S., Pillai, M.R. and Ramamoorthy, N. 2001. Evolution of Tc-99m in diagnostic radiopharmaceuticals. Semin. Nucl. Med., 31:260-77.
4. Barat, B. and Wu, A.M. 2007. Metabolic biotinylation of recombinant antibody by biotin ligase retained in the endoplasmic reticulum. Biomol. Eng., 24:283-91.
5. 99mTc marked CEA antibodies. Indications and clinical value]. Med. Klin (Munich), 87:395-402.
6. 99mTc-labelled anti-CEA monoclonal antibody for tumour immunoscintigraphy: first clinical results. Nucl. Med. Commun., 10:345-52.
7. Begent, R.H., Verhaar, M.J., Chester, K.A. et al. 1996. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med., 2:979-84.
8. Behr, T.M., Becker, W.S., Bair, H.J. et al. 1995. Comparison of complete versus fragmented technetium-99m-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer. J. Nucl. Med., 36:430-41.
9. Behr, T.M., Becker, W.S., Sharkey, R.M. et al. 1996. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J. Nucl. Med., 37:829-33.
10. Berche, C., Mach, J.P., Lumbroso, J.D. et al. 1982. Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: first clinical results using radiolabelled monoclonal antibodies against carcinoembryonic antigen. Br. Med. J. (Clin. Res. Ed), 285:1447-51.
11. Berman, D.S., Kiat, H., Van Train, K. et al. 1994. Dual-isotope myocardial perfusion SPECT with rest thallium-201 and stress Tc-99m sestamibi. Cardiol. Clin., 12:261-70.
12. Blake, P., Johnson, B. and VanMeter, J.W. 2003. Positron emission tomography (PET) and single photon emission computed tomography (SPECT): clinical applications. J. Neuroophthalmol., 23:34-41.
13. Boehm, M.K., Corper, A.L., Wan, T. et al. 2000. Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem. J., 346 Pt 2:519-28.
14. Boerman, O.C., van Schaijk, F.G., Oyen, W.J. et al. 2003. Pretargeted radioimmunotherapy of cancer: progress step by step. J. Nucl. Med., 44:400-11.
15. 3 antagonism. Anti-Cancer Agents Med. Chem., 6:407-28.
16. Cai, W. and Chen, X. 2007a. Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. Front Biosci., 12:4267-79.
17. Cai, W. and Chen, X. 2007b. Nanoplatforms for targeted molecular imaging in living subjects. Small, 3:1840-54.
18. Cai, W. and Chen, X. 2008. Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med., 49 (Suppl 2):113S-28S.
19. 64Cu-labeled cetuximab, a chimeric anti-EGFR. monoclonal antibody. Eur. J. Nucl. Med. Mol. Imaging, 34:850-8.
20. Cai, W., Chen, K., Li, Z.B. et al. 2007b. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J. Nucl. Med., 48:1862-70.
21. Cai, W., Chen, K., Mohamedali, K.A. et al. 2006a. PET of vascular endothelial growth factor receptor expression. J. Nucl. Med., 47:2048-56.
22. Cai, W., Ebrahimnejad, A., Chen, K. et al. 2007c. Quantitative radioimmunoPET imaging of EphA2 in tumour-bearing mice. Eur. J. Nucl. Med. Mol. Imaging, 34:2024-36.
23. Cai, W., Niu, G. and Chen, X. 2008a. Imaging of integrins as biomarkers for tumor angiogenesis. Curr. Pharm. Des., in press.
24. Cai, W., Niu, G. and Chen, X. 2008b. Multimodality imaging of the HER.-kinase axis in cancer. Eur. J. Nucl. Med. Mol. Imaging, 35:186-208.
25. 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J. Nucl. Med., 48:304-10.
26. Cai, W., Rao, J., Gambhir, S.S. et al. 2006b. How molecular imaging is speeding up anti-angiogenic drug development. Mol. Cancer Ther., 5:2624-33.
27. 3. Cancer Res., 66:9673-81.
28. Carcinoembryonic antigen: 1981. its role as a marker in the management of cancer. Summary of an NIH consensus statement. Br. Med. J. (Clin. Res. Ed), 282:373-5.
29. Carmichael, J.A., Power, B.E., Garrett, T.P. et al. 2003. The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. J. Mol. Biol., 326:341-51.
30. Casalini, P., Luison, E., Menard, S. et al. 1997. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization. J. Nucl. Med., 38:1378-81.
31. Chang, C.H., Sharkey, R.M., Rossi, E.A. et al. 2002. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol. Cancer Ther., 1:553-63.
32. Chatziioannou, A.F. 2005. Instrumentation for molecular imaging in preclinical research: Micro-PET and Micro-SPECT. Proc. Am. Thorac. Soc., 2:533-6, 10-11.
33. Chester, K.A., Bhatia, J., Boxer, G. et al. 2000. Clinical applications of phage-derived sFvs and sFv fusion proteins. Dis. Markers, 16:53-62.
34. DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. 2003. The price of innovation: new estimates of drug development costs. J. Health Econ., 22:151-85.
35. Erb, D.A. and Nabi, H.A. 2000. Clinical and technical considerations for imaging colorectal cancers with technetium-99m-labeled antiCEA Fab' fragment. J. Nucl. Med. Technol., 28:12-8; quiz 21.
36. 99mTc-BW 431/26 in the diagnostic workup of patients with colorectal cancer. Int. J. Rad. Appl. Instrum. B., 18:53-7.
37. 99mTc-anti-CEA monoclonal antibody imaging in the diagnosis of recurrent colorectal carcinoma? Q. J. Nucl. Med., 47:109-15.
38. Gambhir, S.S. 2002. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer, 2:683-93.
39. Gambhir, S.S., Czernin, J., Schwimmer, J. et al. 2001. A tabulated summary of the FDG PET literature. J. Nucl. Med., 42:1S-93S.
40. Gasparri, A., Moro, M., Curnis, F. et al. 1999. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models. Cancer Res., 59:2917-23.
41. Gautherot, E., Bouhou, J., Le Doussal, J.M. et al. 1997. Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten. Cancer, 80:2618-23.
42. 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody. Clin. Cancer Res., 5:3177s-82s.
43. 131I-labeled bivalent hapten. J. Nucl. Med., 41:480-7.
44. Ghesani, M., Belgraier, A. and Hasni, S. 2003. Carcinoembryonic antigen (CEA) scan in the diagnosis of recurrent colorectal carcinoma in a patient with increasing CEA levels and inconclusive computed tomographic findings. Clin. Nucl. Med., 28:608-9.
45. Goldenberg, D.M. 1997. Perspectives on oncologic imaging with radiolabeled antibodies. Cancer, 80:2431-5.
46. Goldenberg, D.M. and Nabi, H.A. 1999. Breast cancer imaging with radiolabeled antibodies. Semin. Nucl. Med., 29:41-8.
47. Goldenberg, D.M. and Wegener, W. 1997. Studies of breast cancer imaging with radiolabeled antibodies to carcinoembryonic antigen. Immunomedics Breast Cancer Study Group. Acta. Med. Austriaca, 24:55-9.
48. Goldenberg, D.M., DeLand, F., Kim, E. et al. 1978. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N. Engl. J. Med., 298:1384-6.
49. 99mTc. Cancer Res., 50:909s-21s.
50. Goldenberg, D.M., Juweid, M., Dunn, R.M. et al. 1997. Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy. J. Nucl. Med. Technol., 25:18-23; quiz 34.
51. Goldenberg, D.M., Rossi, E.A., Sharkey, R.M. et al. 2008. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J. Nucl. Med., 49:158-63.
52. Goldstein, M.J. and Mitchell, E.P. 2005. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest, 23:338-51.
53. 99mTc]. Rev. Med. Chil., 119:572-6.
54. Griffin, T.W., Brill, A.B., Stevens, S. et al. 1991. Initial clinical study of indium-111-labeled clone 110 anticarcinoembryonic antigen antibody in patients with colorectal cancer. J. Clin. Oncol., 9:631-40.
55. 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. J. Nucl. Med., 45:30-9.
56. Griffiths, G.L., Goldenberg, D.M., Roesch, F. et al. 1999. Radiolabeling of an anti-carcinoembryonic antigen antibody Fab' fragment (CEA-Scan) with the positron-emitting radionuclide Tc-94m. Clin. Cancer Res., 5:3001s-3s.
57. 99mTc-labelled monoclonal antibody BW 431/26. A critical assessment after 119 studies]. Rofo, 157:3-10.
58. 99mTc-labeling kit for antibody imaging. Cancer Res., 50:794s-8s.
59. Hladik, P., Vizda, J., Bedrna, J. et al. 2001. Immunoscintigraphy and intraoperative radioimmunodetection in the treatment of colorectal carcinoma. Colorectal. Dis., 3:380-6.
60. Hnatowich, D.J., Fritz, B., Virzi, F. et al. 1993. Improved tumor localization with (strept)avidin and labeled biotin as a substitute for antibody. Nucl. Med. Biol., 20:189-95.
61. Holliger, P. and Hudson, P.J. 2005. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol., 23:1126-36.
62. Huston, J.S., Levinson, D., Mudgett-Hunter, M. et al. 1988. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. U.S.A., 85:5879-83.
63. Jia, F., Shelton, T.D. and Lewis, M.R. 2007. Preparation, characterization and biological evaluation of a streptavidin-chimeric t84.66 conjugate for antibody pretargeting. Cancer Biother. Radiopharm., 22:654-64.
64. 99mTc-labeled monoclonal anti-CEA-antibodies. Acta. Oncol., 32:771-8.
65. 188Relabeled peptide. Bioconjug. Chem., 11:842-54.
66. Karacay, H., Sharkey, R.M., Govindan, S.V. et al. 1997. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development. Bioconjug. Chem., 8:585-94.
67. Kaushal, S., McElroy, M.K., Luiken, G.A. et al. 2008. Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer. J. Gastrointest. Surg.
68. Kelloff, G.J., Hoffman, J.M., Johnson, B. et al. 2005. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin. Cancer Res., 11:2785-808.
69. Kenanova, V., Olafsen, T., Williams, L.E. et al. 2007. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res., 67:718-26.
70. Kjaer, A. 2006. Molecular imaging of cancer using PET and SPECT. Adv. Exp. Med. Biol., 587:277-84.
71. 111In-labeled anti-CEA monoclonal antibody. AJR Am. J. Roentgenol., 151:697-703.
72. 99mTc-labelled monoclonal anti-CEA BW 431/26 antibodies in patients with suspected recurrent and metastatic colorectal carcinoma: two-year follow-up. Nucl. Med. Commun., 20:859-65.
73. Li, G.P., Zhang, H., Zhu, C.M. et al. 2005. Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma. World J. Gastroenterol., 11:6288-94.
74. Li, L., Bading, J., Yazaki, P.J. et al. 2008. A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies. Bioconjug. Chem., 19:89-96.
75. Li, L., Yazaki, P.J., Anderson, A.L. et al. 2006. Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody. Bioconjug. Chem., 17:68-76.
76. 99mTc-labeled arcitumomab (CEA-scan) and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann. Surg. Oncol., 8:779-86.
77. 99mTc-labeled monoclonal anti-carcinoembryonic antigen antibody (BW 431/26). Clinical results in the detection of colorectal carcinomas and recurrences. Scand J. Gastroenterol., 24:1205-11.
78. Lind, P., Lechner, P., Arian-Schad, K. et al. 1991a. Anti-carcinoembryonic antigen immunoscintigraphy (technetium-99m-monoclonal antibody BW 431/26) and serum CEA levels in patients with suspected primary and recurrent colorectal carcinoma. J. Nucl. Med., 32:1319-25.
79. Lind, P., Smola, M.G., Lechner, P. et al. 1991b. The immunoscintigraphic use of Tc-99m-labelled monoclonal anti-CEA antibodies (BW 431/26) in patients with suspected primary, recurrent and metastatic breast cancer. Int. J. Cancer, 47:865-9.
80. Liu, Z., Cai, W., He, L. et al. 2007. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol., 2:47-52.
81. 76Br-labeled anti-CEA antibodies in pigs; aspects of dosimetry and PET imaging properties. Med. Phys., 26:249-58.
82. Lovqvist, A., Sundin, A., Ahlstrom, H. et al. 1995. 76Br-labeled monoclonal anti-CEA antibodies for radioimmuno positron emission tomography. Nucl. Med. Biol., 22:125-31.
83. Lovqvist, A., Sundin, A., Ahlstrom, H. et al. 1997a. Pharmacokinetics and experimental PET imaging of a bromine-76-labeled monoclonal anti-CEA antibody. J. Nucl. Med., 38:395-401.
84. Lovqvist, A., Sundin, A., Roberto, A. et al. 1997b. Comparative PET imaging of experimental tumors with bromine-76-labeled antibodies, fluorine-18-fluorodeoxyglucose and carbon-11-methionine. J. Nucl. Med., 38:1029-35.
85. Magnani, P., Paganelli, G., Songini, C. et al. 1996. Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma. Br. J. Cancer, 74:825-31.
86. Malamitsi, J., Kosmidis, P.A., Papadopoulos, S. et al. 2002. Contribution of an Anti-CEA Fab' scan in the detection of medullary thyroid cancer. Clin. Nucl. Med., 27:447-8.
87. Mankoff, D.A. 2007. A definition of molecular imaging. J. Nucl. Med., 48:18N, 21N.
88. Marshall, D., Pedley, R.B., Boden, J.A. et al. 1996. Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody. Br. J. Cancer, 73:565-72.
89. Massoud, T.F. and Gambhir, S.S. 2003. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev., 17:545-80.
90. Mayer, A., Tsiompanou, E., O'Malley, D. et al. 2000. Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin. Cancer Res., 6:1711-9.
91. 124I-labeled hapten-peptide. J. Nucl. Med., 47:1678-88.
92. Mease, R.C. and Lambert, C. 2001. Newer methods of labeling diagnostic agents with Tc-99m. Semin. Nucl. Med., 31:278-85.
93. Moffat, F.L., Jr., Pinsky, C.M., Hammershaimb, L. et al. 1996. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group. J. Clin. Oncol., 14:2295-305.
94. Muller, D., Karle, A., Meissburger, B. et al. 2007. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J. Biol. Chem., 282:12650-60.
95. Nussbaum, S. and Roth, H.J. 2000. Human anti-mouse antibodies: pitfalls in tumor marker measurement and strategies for enhanced assay robustness; including results with Elecsys CEA. Anticancer Res., 20:5249-52.
96. Olafsen, T., Cheung, C.W., Yazaki, P.J. et al. 2004a. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng. Des. Sel., 17:21-7.
97. Olafsen, T., Cheung, C.W., Yazaki, P.J. et al. 2004b. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng. Des. Sel., 17:21-7.
98. Oriuchi, N., Endo, K., Watanabe, N. et al. 1995. Semiquantitative SPECT tumor uptake of technetium-99m-labeled anti-CEA monoclonal antibody in colorectal tumor. J. Nucl. Med., 36:679-83.
99. Patt, Y.Z., Lamki, L.M., Haynie, T.P. et al. 1988. Improved tumor localization with increasing dose of indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 in metastatic colorectal cancer. J. Clin. Oncol., 6:1220-30.
100. Patt, Y.Z., Lamki, L.M., Shanken, J. et al. 1990. Imaging with indium111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases. J. Clin. Oncol., 8:1246-54.
101. Patt, Y.Z., Podoloff, D.A., Curley, S. et al. 1994. Technetium 99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels. J. Clin. Oncol., 12:489-95.
102. Peremans, K., Cornelissen, B., Van Den Bossche, B. et al. 2005. A review of small animal imaging planar and pinhole spect Gamma camera imaging. Vet. Radiol. Ultrasound, 46:162-70.
103. Perez, L., Ayala, M., Pimentel, G. et al. 2006. A multivalent recombinant antibody fragment specific for carcinoembryonic antigen. Biotechnol. Appl. Biochem., 43:39-48.
104. Riva, P., Moscatelli, G., Paganelli, G. et al. 1988. Antibody-guided diagnosis: an Italian experience on CEA-expressing tumours. Int. J. Cancer Suppl., 2:114-20.
105. Rossi, E.A., Chang, C.H., Losman, M.J. et al. 2005. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells. Clin. Cancer Res., 11:7122s-9s.
106. Rudin, M. and Weissleder, R. 2003. Molecular imaging in drug discovery and development. Nat. Rev. Drug Discov., 2:123-31.
107. 99mTc-sestamibi scintimammography in the evaluation of high risk palpable breast lesions. Nucl. Med. Commun., 24:291-6.
108. Schetters, H. 1999. Avidin and streptavidin in clinical diagnostics. Biomol. Eng., 16:73-8.
109. Schneider, J. 2006. Tumor markers in detection of lung cancer. Adv. Clin. Chem., 42:1-41.
110. Serafini, A.N., Klein, J.L., Wolff, B.G. et al. 1998. Radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium 99m-labeled totally human monoclonal antibody 88BV59: results of pivotal, phase III multicenter studies. J. Clin. Oncol., 16:1777-87.
111. Sharkey, R.M., Cardillo, T.M., Rossi, E.A. et al. 2005. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat. Med., 11:1250-5.
112. Sharkey, R.M., Karacay, H., Griffiths, G.L. et al. 1997. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Bioconjug. Chem., 8:595-604.
113. Sharkey, R.M., Karacay, H., McBride, W.J. et al. 2007. Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: an update. Clin. Cancer Res., 13:5577s-85s.
114. Sharkey, R.M., McBride, W.J., Karacay, H. et al. 2003. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res., 63:354-63.
115. 18F labeling for immuno-PET: where speed and contrast meet. J. Nucl. Med., 48:170-2.
116. 99mTc-IMMU4 imaging in recurrent colorectal cancer: efficacy and impact on surgical management. Nucl. Med. Commun., 17:568-76.
117. Stickel, J.R., Qi, J. and Cherry, S.R. 2007. Fabrication and characterization of a 0.5-mm lutetium oxyorthosilicate detector array for high-resolution PET applications. J. Nucl. Med., 48:115-21.
118. Stomper, P.C., D'Souza, D.J., Bakshi, S.P. et al. 1995. Detection of pelvic recurrence of colorectal carcinoma: prospective, blinded comparison of Tc-99m-IMMU-4 monoclonal antibody scanning and CT. Radiology, 197:688-92.
119. Stork, R., Muller, D. and Kontermann, R.E. 2007. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng. Des. Sel., 20:569-76.
120. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J. Nucl. Med., 44:1962-9.
121. 99mTc-labeled anti-CEA monoclonal antibody for patients with colorectal cancer. Anticancer Res., 15:471-5.
122. Ugrinska, A., Bombardieri, E., Stokkel, M.P. et al. 2002. Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer. Q. J. Nucl. Med., 46:88-104.
123. Venisnik, K.M., Olafsen, T., Gambhir, S.S. et al. 2007. Fusion of Gaussia luciferase to an engineered anti-carcinoembryonic antigen (CEA) antibody for in vivo optical imaging. Mol. Imaging Biol., 9:267-77.
124. Venisnik, K.M., Olafsen, T., Loening, A.M. et al. 2006. Bifunctional antibody-Renilla luciferase fusion protein for in vivo optical detection of tumors. Protein Eng. Des. Sel., 19:453-60.
125. Westera, G., Reist, H.W., Buchegger, F. et al. 1991. Radioimmuno positron emission tomography with monoclonal antibodies: a new approach to quantifying in vivo tumour concentration and biodistribution for radioimmunotherapy. Nucl. Med. Commun., 12:429-37.
126. Williams, L.E., Wu, A.M., Yazaki, P.J. et al. 2001. Numerical selection of optimal tumor imaging agents with application to engineered antibodies. Cancer Biother. Radiopharm., 16:25-35.
127. 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma. J. Nucl. Med., 41:1657-63.
128. Willmann, J.K., van Bruggen, N., Dinkelborg, L.M. et al. 2008. Molecular imaging in drug development. Nat. Rev. Drug Discov., 7:591-607.
129. 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin. Cancer Res., 10:5014-21.
130. Wu, A.M. and Senter, P.D. 2005. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol., 23:1137-46.
131. Wu, A.M., Yazaki, P.J., Tsai, S. et al. 2000. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc. Natl. Acad. Sci. U.S.A., 97:8495-500.
132. Yazaki, P.J., Sherman, M.A., Shively, J.E. et al. 2004. Humanization of the anti-CEA T84.66 antibody based on crystal structure data. Protein Eng. Des. Sel., 17:481-9.
133. Yazaki, P.J., Shively, L., Clark, C. et al. 2001a. Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications. J. Immunol. Methods, 253:195-208.
134. Yazaki, P.J., Wu, A.M., Tsai, S.W. et al. 2001b. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. Bioconjug. Chem., 12:220-8.
135. Zbar, A.P., Thomas, H., Wilkinson, R.W. et al. 2005. Immune. responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR.1A3: results of a phase I study. Int. J. Colorectal. Dis., 20:403-14.
136. 18F-FRGD2. J. Nucl. Med., 47:113-21.